Le Lézard
Classified in: Health
Subject: ACC

Medicover AB: Issue and repurchase of class C shares for incentive program


STOCKHOLM, Nov. 6, 2023 /PRNewswire/ -- The board of directors for Medicover AB (publ) has today resolved to issue 1,600,000 new class C shares and to immediately thereafter repurchase such 1,600,000 issued class C shares, for the purpose of the long term performance-based share programs for key individuals as approved by the annual general meetings held on 29 April 2021, 27 April 2022 and 27 April 2023 (the "Plan 2021", the "Plan 2022" and the "Plan 2023").

Today's resolution by the board of directors was passed based on the authorisation granted by the annual general meeting held on 27 April 2023.

Nordea Bank Abp will subscribe for all issued class C shares at a subscription price of EUR 0.2 per share. All such 1,600,000 issued class C shares will be repurchased by Medicover AB (publ) at a purchase price of EUR 0.2 per share. Following the share issue, the share capital will increase by EUR 320,000. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.

The purpose of the share issue and the repurchase is to enable future delivery of performance shares in accordance with the incentive programs the Plan 2021, the Plan 2022 and the Plan 2023 as well as to cover any social charges associated with the programs. The class C shares will be converted to class B shares before delivery to the participants in the programs.

Medicover AB (publ) currently holds 2,282,822 class C shares and will, following the repurchase of the new 1,600,000 issued class C shares, hold all 3,882,822 class C shares in the company.

For further information, please contact:

Hanna Bjellquist, Head of Investor Relations
+46 703 033 272
[email protected] 

Medicover is required to publish the information contained in this press release pursuant to the Swedish Financial Instruments Trading Act. The information was provided for publication by the abovementioned contact person at 08.30 CET on 6 November 2023.

Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities, laboratories and blood-drawing points and the largest markets are Poland, Germany, Romania and India. In 2022, Medicover had revenue of ?1,510 million and more than 44,000 employees. For more information, go to www.medicover.com

The following files are available for download:

https://mb.cision.com/Main/15662/3869662/2408589.pdf

Issue and repurchase of class C shares for incentive program

 


These press releases may also interest you

at 18:00
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...

at 12:18
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 11:10
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform. Panda Health...



News published on and distributed by: